In-Vitrodn-Vivo Correlation of Drug Liberation with an Extended Release Peroral Dosage form for Iloprost in Man
暂无分享,去创建一个
[1] M. Hildebrand. Interspecies Comparison of Pharmacokinetic Parameters of an Oral Sustained Release Preparation of Iloprost , 1994 .
[2] B. Hazleman,et al. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. , 1992, The Journal of rheumatology.
[3] M. Hildebrand,et al. Comparison of bioanalytical determinations of Iloprost, a chemically stable PGI2 mimetic, by conventional radioimmunoassay (RIA) and scintillation proximity assay (SPA). , 1992, Eicosanoids.
[4] R. Madhok,et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. , 1991, Annals of the rheumatic diseases.
[5] F. McDonald,et al. Characterization of oral sustained release preparations of iloprost in a pig model by plasma level monitoring. , 1991, Prostaglandins.
[6] T. Staks,et al. Oral iloprost in healthy volunteers. , 1991, Eicosanoids.
[7] J. Fiessinger,et al. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans , 1990, The Lancet.
[8] M. Jünger,et al. Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease. , 1990, Eicosanoids.
[9] B. Nieuweboer,et al. Development, validation and practical use of a sensitive and specific radioimmunoassay for the determination of iloprost. , 1990, Eicosanoids.
[10] H. Möller. Gastro-duodenale Absorption von Indometacin , 1989 .
[11] M. Karmazyn. Reduction of enzyme release from reperfused ischemic hearts by steroidal and non-steroidal prostaglandin synthesis inhibitors. , 1983, Prostaglandins, leukotrienes, and medicine.
[12] W. Losert,et al. Comparison of the vasodepressor action of ZK 36 374, a stable prostacyclin derivative, PGI2 and PGE1 with their effect on platelet aggregation and bleeding time in rats. , 1983, Prostaglandins, leukotrienes, and medicine.
[13] A. Scriabine. New drugs annual : cardiovascular drugs , 1983 .
[14] J. Vane,et al. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. , 1976, Prostaglandins.
[15] J. Vane,et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.
[16] S. Riegelman,et al. New method for calculating the intrinsic absorption rate of drugs. , 1968, Journal of pharmaceutical sciences.
[17] Gerhard Levy,et al. Development of In Vitro Dissolution Tests which Correlate Quantitatively with Dissolution Rate-Limited Drug Absorption in Man , 1965 .
[18] J. Wagner,et al. Per cent absorbed time plots derived from blood level and/or urinary excretion data. , 1963, Journal of pharmaceutical sciences.